Introduction
Cancer immunotherapy, particularly immune checkpoint inhibition (ICI) and adoptive cell therapy (ACT), has established itself as a cornerstone of modern oncology. While these treatments offer curative potential for some, a significant portion of patients with advanced solid and liquid tumors do not achieve a durable response. Understanding the principal mechanisms that determine Cancer Immune Responsiveness (CIR) is critical for improving patient outcomes. This review by the Society for Immunotherapy of Cancer (SITC) provides a holistic framework for CIR, moving beyond a tumor-centric view to include patient-specific genetic factors, lifestyle influences, and the intrinsic biology of the tumor microenvironment (TME).
The Multidimensional Nature of CIR
The central challenge in contemporary immunotherapy is overcoming primary and secondary resistance. Historically, research focused heavily on tumor mutations. However, CIR is now recognized as a multifactorial phenomenon driven by a "plurality of factors." These range from inherited germline variants to modifiable host factors like the gut microbiome, diet, and exercise.
As illustrated above, determinants of response can be categorized into systemic and localized factors. Systemic factors include non-modifiable germline genetics and modifiable host factors, while localized factors center on the tumor microenvironment. These interactions culminate in distinct immune phenotypes: "desert," "excluded," or "infiltrated" tumors, which directly influence the efficacy of approved therapeutic strategies like checkpoint blockade and cell therapies.
Methodological Innovations in Immunotherapy Research
The synthesis of CIR requires advanced analytical techniques to bridge the gap between clinical observation and biological mechanism. The SITC review highlights several key technological shifts:
- High-Resolution Spatial Technologies: Moving beyond bulk sequencing, single-cell RNA-seq (scRNA-seq) and spatial transcriptomics allow researchers to map gene activity within the specific architecture of the tumor, identifying where immune cells are located relative to malignant cells.
- Genome-Wide Association Studies (GWAS): These are instrumental in identifying low-penetrance genetic variants that subtly but significantly influence immune system function.
- AI-Enhanced Histopathology: Deep learning models are now being used to predict complex molecular signatures, such as the "Immunological Constant of Rejection," directly from standard hematoxylin and eosin (H&E) stained slides, offering a low-cost path to precision medicine.
These methods leverage massive datasets, including The Cancer Genome Atlas (TCGA) and specialized consortia like IO-GEM and CIGGI, which pool germline data from immunotherapy-treated cohorts.
Key Determinants: From Germline to Lifestyle
The Germline-TME Axis
Inherited DNA is not merely a passive blueprint; it actively shapes the functional orientation of the TME. Specific germline variants in interferon (IFN) signaling pathways, such as STING or IFIH1, can predispose a patient's tumor to be either an "immune desert" or "infiltrated."
Host Factors and the "Obesity Paradox"
Lifestyle factors present significant opportunities for therapeutic intervention. Interestingly, higher BMI has been associated with better responses to ICI—a phenomenon known as the "obesity paradox." It is hypothesized that obesity-induced leptin may drive T-cells into an exhausted state that, paradoxically, makes them more responsive to reactivation by checkpoint inhibitors.
Furthermore, diet serves as a potent therapeutic lever. Bacterial fermentation of dietary fiber produces short-chain fatty acids (SCFAs) that enhance systemic IFN-γ responses. Clinical data suggest that even modest increases in fiber intake (5g/day) can correlate with a 30% reduction in the risk of cancer progression.
Therapeutic Progress and Challenges
The landscape of approved therapies continues to expand. The approval of Relatlimab (anti-LAG-3) represents the first successful addition to the checkpoint inhibitor family beyond PD-1 and CTLA-4. In the realm of cell therapies, CAR-T cells have achieved remarkable remission rates (40-90%) in hematological malignancies.
However, solid tumors remain a formidable challenge. The "hostile" TME—characterized by acidity, hypoxia, and immunosuppression—often leads to poor CAR-T trafficking and rapid exhaustion. Future efforts are focused on developing "armored" CAR-Ts designed to survive and function within these suppressive environments.
Limitations and Future Perspectives
Despite rapid progress, several hurdles remain:
- Statistical Power: Detecting subtle germline influences requires massive cohorts (>5,000 patients), necessitating international data sharing.
- Neoantigen Prediction: Current biomarkers only scratch the surface of immunogenic potential; better modeling of MHC-mutation binding is required.
- Clinical Scalability: While spatial tools provide deep insights, their cost and complexity currently limit routine clinical application.
By integrating systemic host factors with localized tumor biology, the field is moving toward a more personalized and effective approach to cancer immunotherapy.
Summary updated